ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 44, Issue 5, 2003, Pages 801-806

  Santoro, P ^a   Martinelli, Giovanni ^a   Ferrucci, P F ^a   Mingrone, W ^b   Cocorocchio, E ^a   Conconi, A ^b   Peccatori, F A ^a   De Luzio, K ^a   Mazzetta, C ^a   Zucca, E ^b   Cavalli, F ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Adriamycin; CHOP; Elderly patients; Non Hodgkin's lymphoma

Indexed keywords

ANTICOAGULANT AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; VINCRISTINE;

AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CARDIOTOXICITY; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PARESTHESIA; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG EVALUATION; FEMALE; HUMANS; LEUKOPENIA; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; NEUTROPENIA; PREDNISONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0037402491     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000067981     Document Type: Article

References (28)

1. Coiffier, B., Biron, P., Bastion, Y., et al. (1996) "Elderly lymphoma patients have a long survival if treated with curative intent. A study from the GELA on 453 patients older than 69 years", Proc. Am. Soc. Clin. Oncol. 15, 417, Abstract 1279.
2. Dixon, D.O., Neilan, B., Jones, S.E., et al. (1986) "Effect of age on therapeutic outcome in advanced diffuse histocytic lymphoma: the Southwest Oncology Group experience", J. Clin. Oncol. 4, 295-305.
3. Kwak, L.W., Halpern, J., Olshen, R.A., et al. (1990) "Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: a tree-structured survival analysis", J. Clin. Oncol. 8, 963-977.
4. LePage, E., Gisselbrecht, C., Haioun, C., et al. (1993) "Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol", Ann. Oncol. 4, 651-656.
5. Solal-Celigny, P., Chastang, C., Herrera, A., et al. (1987) "Age as the main prognostic factor in adult aggressive NHL", Am. J. Med. 83, 1075-1079.
6. Vose, J.M., Armitage, J.O., Weisemburger, D.D., et al. (1988) "The importance of age in survival of patients treated with chemotherapy for aggressive NHL", J. Clin. Oncol. 6, 1838-1844.
7. Shipp, M.A., Harrington, D.P., Anderson, J.R., et al. (1993) "A predictive model for aggressive NHL: the International NHL prognostic factors project", N. Engl. J. Med. 329, 987-994.
8. Grogan, L., Corbally, N., Dervan, P.A., Byrne, A. and Carney, D.N. (1994) "Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose adriamycin-based regimens", Ann. Oncol. 5(Suppl. 2), 47-51.
9. Tirelli, U., Errante, D., Van Glabbeke, M., et al. (1998) "CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group", J. Clin. Oncol. 16, 27-34.
10. Meyer, R.M., Browman, G.P., Samosh, M.L., et al. (1995) "Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma", J. Clin. Oncol. 13, 2386-2393.
11. Sonneveld, P., de Ridder, M., van der Lelie, H., et al. (1995) "Comparison of adriamycin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy", J. Clin. Oncol. 13, 2530-2539.
12. Gomez, H., Mas, L., Casanova, L., et al. (1998) "Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematological toxicity", J. Clin. Oncol. 16, 2352-2358.
13. Martelli, M., Guglielmi, C., Coluzzi, S., et al. (1993) "P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma", J. Clin. Oncol. 11, 2362-2369.
14. Bertini, M., Freilone, R., Vitolo, U., et al. (1996) "The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen", Leuk. Lymphoma 22, 483-493.
15. Bessell, E.M., Coutts, A., Fletcher, J., et al. (1994) "Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate- or high-grade histology", Eur. J. Cancer 30A, 1337-1341.
16. Tirelli, U., Zagonel, V., Errante, D., et al. (1992) "A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma", J. Clin. Oncol. 10, 228-236.
17. Jones, S.E., Grozea, P.N. and Metz, E.N. (1979) "Superiority of adriamycin-containing combination therapy in the treatment of diffuse lymphoma. A Southwest Oncology Group Study", Cancer 43, 417-425.
18. Bajetta, E., Valagussa, P., Bonadonna, G., et al. (1988) "Combined modality treatment for stage I-II LNH: CVP versus BACOP chemotherapy", Int. J. Radiat. Oncol. Biol. Phys. 1, 3-12.
19. Millar, T.P. and Jones, S.E. (1983) "Initial chemotherapy for clinically localized lymphomas of unfavorable histology", Blood 52, 413-418.
20. Cheeson, B.D., et al. (1999) "Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphoma", J. Clin. Oncol. 17, 1244-1253.
21. National Cancer Institute's (NCI) Common Toxicity Criteria. Version 2.0, June 1 1999. www http: www.ctep-dev.cancer.gov/reporting/ctc.html.
22. Hryniuk, W.M. (1988) "The importance of dose intensity in the outcome of chemotherapy", In: Hellman, S., De Vita, V. and Rosemberg, S., eds, Important Advances in Oncology (Philadelphia 1988) (Philadelphia, JB, Lippincott), pp. 121-141.
23. Hosmer, D.W. and Lemeshow, S. (2002) Applied Logistic Regression. Edit (Wiley Interscience, New York, 1989).
24. S-PLUS 2000 Professional Release 2 Copyright (c) 1988-1989 MathSoft, Inc.
25. Fisher, R.I., Gaynor, E.R., Dahlberg, S., et al. (1993) "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced NHL", N. Engl. J. Med. 328, 1002-1006.
26. Armitage, J.O. and Potter, J.F. (1984) "Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. Increased complications of advancing age", J. Am. Geriatr. Soc. 32, 269-273.
27. Radford, J.A., Whelan, J.S., Rohatiner, A.Z., et al. (1994) "Weekly VAPEC-B chemotherapy for high grade NHL: results of treatment in 184 patients", Ann. Oncol. 5/2, 47-51.
28. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. and Gisselbrecht, C. (2002) "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N. Engl. J. Med. 346(4),